Metabolic Reprogramming Target & High-Purity Reagents for Glutamine Transport Inhibition Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC1A5/ASCT2 drug discovery. Because SLC1A5 is a complex multi-pass membrane transporter, cell-based assays are the only reliable way to preserve its native conformation. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC1A5/ASCT2 Extracellular Loop-Fc / Mutant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed. | View SLC1A5 Products |
| Gene Delivery | SLC1A5/ASCT2 Lentivirus Particles. Full-length ORF with C-terminal tag, HEK293 expressed. High titer (>10^8 TU/ml). For stable cell line generation preserving native 11-TM topology. | View SLC1A5 Products |
| Promise-ORF | SLC1A5/ASCT2 Promise-ORF Clone. Sequence-verified wild-type and reported mutant variants. Ready for transfection or lentiviral packaging. | View SLC1A5 Products |
| Benchmark Ab | Anti-SLC1A5 Benchmark Antibody. Recombinant positive control for flow cytometry / internalization. Sequence Verified. | View SLC1A5 Products |
| Validator | SLC1A5 siRNA Set (3 unique targets). Chemically synthesized, HPLC purified (>95%). For knockdown verification and specificity controls. | View SLC1A5 Products |
| Related Target: SLC1A4 | SLC1A4 (ASCT1). Closest paralog; essential for selectivity counter-screening. | View SLC1A4 Products |
| Related Target: SLC7A5 | SLC7A5 (LAT1). L-type amino acid transporter 1. Compensatory glutamine uptake pathway. Critical for counter-screening. | View SLC7A5 Products |
| Related Target: SLC38A1 | SLC38A1 (SNAT1). Sodium-coupled neutral amino acid transporter. Glutamine transport redundancy analysis. | View SLC38A1 Products |
| Related Target: GLS1 | GLS1 (Glutaminase). Downstream metabolic enzyme. Pathway combination therapy target. | View GLS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| 11-Transmembrane Topology (Complex Membrane) | Full-Length Lentivirus Particles. HEK293 expressed. Preserves native glycosylation and conformational epitopes for antibody screening. Sequence verified by NGS. |
| Functional Transport Assay (Glutamine Uptake) | High-Titer Lentivirus (>10^8 TU/ml) enables stable overexpression in CHO or HEK293. Compatible with radioactive (³H-glutamine) or fluorescent amino acid uptake assays. |
| Cross-species Preclinical Evaluation (Cyno/Mouse) | Human/Mouse/Cynomolgus ortholog lentivirus available. Sequence alignment >95% for extracellular loops. Endotoxin controlled (<1 EU/µg). |
| Compensatory Pathway Analysis (SLC Family Selectivity) | Homolog Panel: SLC1A4 (ASCT1), SLC7A5, SLC38A1 lentivirus available for counter-screening. Eliminate off-target transporter inhibition. |
| Specificity Verification | Validated siRNA set included. Demonstrate target-specific knockdown of glutamine uptake vs. non-targeting controls. |
| Lack of Reliable Controls | Sequence-verified recombinant benchmark antibodies included for baseline assay calibration. |
| False Positives in Cellular Assays | Validated siRNA sets included for rigorous biological specificity checks in glutamine uptake models. |
Live SLC1A5/ASCT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (SLC1A5)
- ➤ View Active Clinical Trials (ASCT2)
- ➤ Latest Resistance & Mechanism Research (PubMed)
- ➤ Latest Resistance Research (alternative)
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for SLC1A5/ASCT2 therapeutics is intensifying as the industry capitalizes on "glutamine addiction" in solid tumors, particularly triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). While first-generation tool compounds (e.g., V-9302, GPNA) have established proof-of-concept, the current pipeline is shifting toward next-generation small molecule inhibitors with improved selectivity profiles and toward biologic modalities. Monoclonal antibodies and antibody-drug conjugates (ADCs) designed to recognize extracellular loops are emerging as potent alternatives. As first-generation therapies mature, the next wave of R&D is targeting optimal internalization kinetics and combinatorial approaches with mTOR inhibitors, glutaminase (GLS1) inhibitors, or immune checkpoint blockade. Combination strategies are expected to dominate Phase I/II trial designs over the next three years.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Calithera Biosciences, VU University Medical Center, EMD Serono, Duke University, Early-stage biotech | Solid Tumors (TNBC, PDAC, NSCLC) | Functional Uptake & Selectivity Assay (Need high-expression lentivirus for quantitative ³H-glutamine transport and homolog counter-screening) |
| Monoclonal Antibody (Anti-ECD) | Academic/Discovery Phase, Preclinical Biotechs | Hematologic Malignancies, Solid Tumors, Melanoma, Colorectal Cancer | Epitope Mapping (Need high-purity Extracellular Loop Recombinant Proteins and native conformation cell lines via lentivirus) |
| Antibody-Drug Conjugate (ADC) | Emerging ADC Pipelines, Asian pharma groups | Lung Cancer, Prostate Cancer, Metastatic solid tumors | Internalization Assay (Need robust cell-based expression models and pH-sensitive internalization kinetics) |
| Combination Therapy (Metabolic) | Institutional Consortia, Calithera (GLS1) | Refractory Metastatic Cancers | Pathway Panel Screening (Need SLC1A5 + GLS1 co-expression systems, SLC7A5, SLC38A1 reagents) |
Molecular Differentiation & Assay Strategy
To achieve best-in-class targeting of SLC1A5/ASCT2, drug discovery programs must address:
- Selectivity: Strictly distinguish from paralogs such as SLC1A4 (ASCT1, ~60% sequence similarity) and other glutamine transporters (SLC7A5, SLC38A1). Off-target inhibition can lead to unpredictable toxicity.
- Functional vs. Binding Inhibition: Distinguish competitive from allosteric inhibitors; requires transport activity assays (e.g., ³H-glutamine uptake) in addition to binding assays.
- Internalization Kinetics (for ADCs): High-efficiency pH-dependent internalization and lysosomal escape are critical for ADC efficacy. Requires real-time tracking using pH-sensitive dyes.
- Cross-Species Reactivity: Preclinical studies require human/monkey/mouse ortholog validation due to high conservation in transmembrane domains but differences in extracellular loops.
Recommended Screening Assays:
- Cell-Based Binding / Flow Cytometry: Use stable cell lines expressing full-length human/cynomolgus SLC1A5 for FACS screening. Most reliable first-line assay.
- Glutamine Uptake Inhibition Assay: Use radiolabeled or fluorescently labeled substrates to assess functional blockade.
- Internalization Kinetics Assay (for ADCs): Label candidate antibodies with pH-sensitive dyes and monitor intracellular trafficking in real time.
TarMart Solution Summary
SLC1A5 is a challenging multi-pass membrane protein that cannot be faithfully represented by soluble recombinant fragments alone. TarMart offers a comprehensive toolkit built on cell-engineering and gene delivery:
- Lentivirus for Stable Cell Lines: Full-length ORF cloned into lentiviral vectors with high titer (>10⁸ TU/ml), allowing generation of HEK293/CHO stable cell pools that preserve native conformation for antibody screening and functional assays.
- Extracellular Loop ECD-Fc Proteins: Truncated fusion proteins (purity >95%, endotoxin <1 EU/µg) covering specific loops (e.g., Loop 2) for early-stage hybridoma screening and epitope mapping.
- Multi-Species ORF Library: Human, mouse, and cynomolgus SLC1A5 ORFs sequence-verified by NGS, supporting cross-species DMPK studies.
- Control Reagents: Sequence-verified benchmark antibodies and validated siRNA sets (3 unique targets) for rigorous assay baseline and specificity checks.
Related Targets for Cross-Selling
When discussing SLC1A5 projects, recommended associated targets to offer:
- View SLC7A5 Products (LAT1): Complementary glutamine transporter; dual inhibition blocks metabolic bypass resistance.
- View SLC1A4 Products (ASCT1): Closest paralog; essential for selectivity profiling.
- View SLC38A1 Products (SNAT1): Alternative glutamine transporter in neuronal and certain cancer cells.
- View GLS1 Products (Glutaminase): Downstream metabolic enzyme; combination targeting shows synthetic lethality.